A relook at preventive therapy for tuberculosis in children

Area of Science:

• Pediatric infectious diseases
• Public health strategies
• Tuberculosis control

Background:

• Preventive therapy is vital for controlling pediatric tuberculosis (TB).
• In low TB burden settings, it prevents new infections across all ages.
• In high TB burden settings, it prevents disease in infected individuals but not reinfection.

Purpose of the Study:

• To highlight the importance of preventive therapy in pediatric TB control.
• To identify high-risk groups for preventive therapy in high TB burden settings.
• To discuss current preferred regimens and the need for short-course alternatives.

Main Methods:

• Review of current strategies for pediatric TB prevention.
• Focus on the role of preventive therapy in different epidemiological settings.
• Identification of key populations targeted for preventive therapy.

Main Results:

• Children under 5 and immunocompromised children are primary targets for preventive therapy in high-burden areas.
• A 6-month isoniazid (INH) regimen remains the standard preventive therapy.
• Research is ongoing to develop shorter preventive therapy courses using rifampicin and other drugs.

Conclusions:

• Preventive therapy is a cornerstone of pediatric TB control, complementing diagnosis and treatment.
• Targeted application in high-risk groups is essential in high TB burden countries.
• Development of short-course preventive therapies is a critical area for future research.